10-Q: AccuStem Sciences Reports Third Quarter 2024 Results, Faces Liquidity Challenges

AccuStem Sciences reports a net loss of $1.13 million for the nine months ended September 30, 2024, and acknowledges the need for additional financing to continue operations.

Summary

• AccuStem Sciences, a life sciences company focused on cancer diagnostics, reported its financial results for the third quarter of 2024.
• The company incurred a net loss of $328,174 for the three months ended September 30, 2024, and a net loss of $1,133,001 for the nine months ended September 30, 2024.
• These losses are primarily due to research and development expenses and general and administrative costs.
• As of September 30, 2024, the company had an accumulated deficit of $7,654,946.
• The company's cash balance was $37,080 as of September 30, 2024, which is deemed insufficient to support operations for the next 12 months.
• AccuStem is actively seeking additional equity financing through private and public offerings to fund its operations and research activities.
• The company is developing StemPrintER, a genomic test for breast cancer, and is working towards commercial launch in the US.
• The company has partnered with EmeritusDx for processing and testing of StemPrintER results and is working towards CLIA certification.
• The company has not generated any revenue to date and anticipates operating losses to continue for the foreseeable future.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including substantial losses, insufficient cash, and a material weakness in internal controls. While there is progress in product development, the overall tone is negative due to the company's precarious financial situation and reliance on future capital raises.

Positives

• The company has made progress in the development of StemPrintER, a genomic test for breast cancer.
• AccuStem has partnered with a commercial laboratory, EmeritusDx, to process and test StemPrintER results.
• The company is actively pursuing additional equity financing to address its capital needs.
• General and administrative expenses have decreased compared to the same period last year due to cost saving measures.

Negatives

• The company has incurred significant net losses and has an accumulated deficit of $7,654,946 as of September 30, 2024.
• The company's cash balance of $37,080 is insufficient to support operations for the next 12 months.
• The company has not generated any revenue to date and anticipates operating losses to continue.
• The company has identified a material weakness in its internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• There is no assurance that the company will be able to obtain additional financing on acceptable terms or at all.
• Failure to obtain additional financing could force the company to delay, reduce, or eliminate research and development programs.
• The company is subject to risks associated with the development and commercialization of its products.
• The company has identified a material weakness in its internal controls over financial reporting, which could lead to misstatements in financial reporting.
• The company is dependent on key individuals and the loss of any of these individuals could adversely affect the business.

Future Outlook

The company anticipates operating losses to continue for the foreseeable future and will require significant additional cash resources to continue its planned research and development activities. The company is actively pursuing additional equity financing in the form of a private investment and public equity.

Management Comments

• Management believes that the Company does not have sufficient cash and current assets to support its operations through at least 12 months from the issuance date of these condensed consolidated financial statements.
• Management determined it is appropriate to continue to adopt the going concern basis in preparing the condensed consolidated financial statements.
• Management intends to remediate the material weakness in internal controls by recruiting appropriately skilled accounting resources.

Industry Context

The company operates in the competitive field of cancer diagnostics and personalized medicine. The development and commercialization of genomic tests is a growing area, with many companies seeking to provide better diagnostic and prognostic tools for cancer patients. AccuStem's focus on tumor stemness and its StemPrintER test positions it in a specific niche within this broader market.

Comparison to Industry Standards

• AccuStem's financial situation is not uncommon for early-stage biotech companies that are pre-revenue and focused on research and development.
• Many companies in the diagnostics space rely on external funding to support their operations until they can achieve commercialization and generate revenue.
• The company's partnership with EmeritusDx is a common strategy for biotech companies to outsource laboratory testing and accelerate the commercialization process.
• The company's focus on breast cancer is a large market, with several competitors offering similar prognostic tests, such as Oncotype DX and MammaPrint.
• AccuStem's StemPrintER test is differentiated by its focus on tumor stemness, which could provide a unique value proposition if validated in clinical practice.

Corporate Governance

Related Party Transactions

• Tiziana Life Sciences Limited is a related party due to common control, and the company shares directors, officers, and significant shareholders.
• The company has a shared services agreement with Tiziana, where it outsources certain management and administrative services.
• As of September 30, 2024, $2,104,062 was due to Tiziana for expenses paid on behalf of the company.
• Gabriele Cerrone, the Chairman of the Board of Directors, provides consulting services to the company for a monthly fee of $5,500, and $181,500 was due to him as of September 30, 2024.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and need for additional financing.
• Employees may be impacted by potential cost-cutting measures or delays in research and development programs.
• Customers and patients may experience delays in the availability of the StemPrintER test.
• Suppliers and creditors may face increased risk due to the company's financial challenges.

Next Steps

• The company will continue to work on technology transfer with EmeritusDx.
• The company will seek CLIA certification for its laboratory partner.
• The company plans to launch StemPrintER in the US market.
• The company will continue to pursue additional equity financing.
• The company will continue to evaluate clinical need and revenue opportunity in other markets.

Key Dates

Keywords

AccuStem Sciences, StemPrintER, genomic test, breast cancer, diagnostics, financial results, net loss, liquidity, equity financing, CLIA certification, research and development, operating expenses